Cipla recalls 7,228 bottles of overactive bladder treatment drug in America

As per the USFDA, a class II recall is initiated in a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3kUOVS6
via IFTTT